Helius Medical Technologies, Inc. to Release Second Quarter 2024 Financial Results on August 12, 2024
Helius Medical Technologies (NASDAQ: HSDT), a neurotech company focused on innovative therapeutic neuromodulation for balance and gait deficits, has announced its plans to release second quarter 2024 financial results on August 12, 2024, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. Eastern Time to discuss the results and provide an expanded business update.
The call will feature Dane C. Andreeff, President and CEO, and Jeffrey S. Mathiesen, CFO, who will share insights on Helius' progress and plans for the U.S. commercialization of PoNS®. Investors and interested parties can access the audio call via registration and join the webcast through the provided link. The webcast will be archived in the Newsroom section of Helius' investor relations website for future reference.
Helius Medical Technologies (NASDAQ: HSDT), un'azienda nel settore neurotecnologico focalizzata su innovative neuromodulazioni terapeutiche per deficit di equilibrio e deambulazione, ha annunciato i suoi piani per rilasciare i risultati finanziari del secondo trimestre 2024 il 12 agosto 2024, dopo la chiusura del mercato. L'azienda terrà una conferenza telefonica e una diretta web lo stesso giorno alle 16:30 ora orientale per discutere i risultati e fornire un aggiornamento aziendale dettagliato.
La chiamata vedrà la partecipazione di Dane C. Andreeff, Presidente e CEO, e Jeffrey S. Mathiesen, CFO, i quali condivideranno approfondimenti sui progressi di Helius e sui piani per la commercializzazione negli Stati Uniti di PoNS®. Gli investitori e le parti interessate possono accedere alla chiamata audio tramite registrazione e partecipare alla diretta web tramite il link fornito. La diretta sarà archiviata nella sezione Notizie del sito web per le relazioni con gli investitori di Helius per future consultazioni.
Helius Medical Technologies (NASDAQ: HSDT), una empresa de neurotecnología enfocada en la neuromodulación terapéutica innovadora para déficits de equilibrio y marcha, ha anunciado sus planes para publicar los resultados financieros del segundo trimestre de 2024 el 12 de agosto de 2024, después del cierre del mercado. La empresa llevará a cabo una conferencia telefónica y un webcast el mismo día a las 4:30 p.m. hora del Este para discutir los resultados y proporcionar una actualización detallada del negocio.
La llamada contará con la participación de Dane C. Andreeff, Presidente y CEO, y Jeffrey S. Mathiesen, CFO, quienes compartirán información sobre el progreso de Helius y los planes para la comercialización de PoNS® en EE. UU.. Los inversores y las partes interesadas pueden acceder a la llamada de audio mediante registro y unirse al webcast a través del enlace proporcionado. El webcast será archivado en la sección de Noticias del sitio web de relaciones con inversores de Helius para futura referencia.
Helius Medical Technologies (NASDAQ: HSDT), 균형 및 보행 결핍 치료를 위한 혁신적인 신경 조절 기술에 중점을 둔 신경 기술 회사가 2024년 2분기 재무 결과를 2024년 8월 12일 마감 후 발표할 계획을 발표했습니다. 회사는 같은 날 동부 표준시 기준으로 오후 4시 30분에 결과를 논의하고 확장된 비즈니스 업데이트를 제공하기 위해 전화 회의 및 웹캐스트를 실시할 예정입니다.
이번 통화에는 Dane C. Andreeff, 대통령 겸 CEO, Jeffrey S. Mathiesen, CFO가 참여하여 Helius의 진전 및 PoNS®의 미국 상용화 계획에 대한 통찰을 공유할 것입니다. 투자자 및 관계자는 등록을 통해 오디오 통화에 접근하고 제공된 링크를 통해 웹캐스트에 참가할 수 있습니다. 웹캐스트는 Helius의 투자자 관계 웹사이트의 뉴스룸 섹션에 보관되어 향후 참조를 위해 기록될 것입니다.
Helius Medical Technologies (NASDAQ: HSDT), une entreprise de neurotechnique spécialisée dans la neuromodulation thérapeutique innovante pour les déficits d'équilibre et de marche, a annoncé ses plans de publication des résultats financiers du deuxième trimestre 2024 le 12 août 2024, après la fermeture des marchés. L'entreprise tiendra une conférence téléphonique et un webinaire le même jour à 16h30 heure de l'Est pour discuter des résultats et fournir une mise à jour commerciale détaillée.
Ce appel sera animé par Dane C. Andreeff, Président et CEO, et Jeffrey S. Mathiesen, CFO, qui partageront des informations sur les progrès de Helius et les plans pour la commercialisation de PoNS® aux États-Unis. Les investisseurs et les parties intéressées peuvent accéder à l'appel audio par inscription et rejoindre le webinaire via le lien fourni. Le webinaire sera archivé dans la section Actualités du site Web des relations avec les investisseurs de Helius pour une référence future.
Helius Medical Technologies (NASDAQ: HSDT), ein Neurotech-Unternehmen, das sich auf innovative therapeutische Neuromodulation zur Behandlung von Gleichgewichtsstörungen und Gehdefiziten konzentriert, hat seine Pläne bekannt gegeben, die Finanzergebnisse des zweiten Quartals 2024 am 12. August 2024 nach Börsenschluss zu veröffentlichen. Das Unternehmen wird am selben Tag um 16:30 Uhr Eastern Time eine Telefonkonferenz und einen Webcast abhalten, um die Ergebnisse zu erörtern und eine erweiterte Unternehmensaktualisierung bereitzustellen.
Bei dem Anruf werden Dane C. Andreeff, Präsident und CEO, sowie Jeffrey S. Mathiesen, CFO, teilnehmen, die Einblicke in die Fortschritte von Helius und die Kommerzialisierungspläne für PoNS® in den USA geben werden. Investoren und interessierte Parteien können über eine Registrierung auf den Audioanruf zugreifen und über den bereitgestellten Link am Webcast teilnehmen. Der Webcast wird im Nachrichtenbereich der Investor-Relations-Website von Helius für zukünftige Referenzen archiviert.
- Scheduled release of Q2 2024 financial results
- Planned conference call and webcast to discuss results and provide business updates
- Focus on U.S. commercialization progress of PoNS® device
- None.
NEWTOWN, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Company will release its second quarter 2024 financial results on Monday, August 12, 2024, after the market closes.
Dane C. Andreeff, President and Chief Executive Officer, and Jeffrey S. Mathiesen, Chief Financial Officer will host a conference call to discuss the results and provide an expanded business update regarding Helius’ progress and plans surrounding the U.S. commercialization of PoNS® as follows:
| Date: | Monday, August 12, 2024 |
| Time: | 4:30 p.m. Eastern Time |
| Register (Audio only): | Click Here |
| Webcast: | Click Here |
The webcast will be archived under the Newsroom section of the Company’s investor relations website.
About Helius Medical Technologies, Inc.
Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using an orally applied technology platform that amplifies the brain’s ability to engage physiologic compensatory mechanisms and promote neuroplasticity, improving the lives of people dealing with neurologic diseases. The Company’s first commercial product is the Portable Neuromodulation Stimulator. For more information about the PoNS® or Helius Medical Technologies, visit www.heliusmedical.com.
About the PoNS Device and PoNS Therapy
The Portable Neuromodulation Stimulator (PoNS) is an innovative, non-implantable, orally applied therapy that delivers neurostimulation through a mouthpiece connected to a controller and it’s used, primarily at home, with physical rehabilitation exercise, to improve balance and gait. The PoNS device, which delivers mild electrical impulses to the tongue, is indicated for use in the United States as a short-term treatment of gait deficit due to mild-to-moderate symptoms from multiple sclerosis (“MS”) and is to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only.
PoNS has shown effectiveness in treating gait or balance and a significant reduction in the risk of falling in stroke patients in Canada, where it received authorization for sale in three indications: (i) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from stroke and is to be used in conjunction with physical therapy; (ii) for use as a short-term treatment (14 weeks) of chronic balance deficit due to mild-to-moderate traumatic brain injury (“mmTBI”) and is to be used in conjunction with physical therapy; and (iii) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS and is to be used in conjunction with physical therapy. PoNS is also authorized for sale in Australia for short term use by healthcare professionals as an adjunct to a therapeutic exercise program to improve balance and gait. For more information visit www.ponstherapy.com.
Investor Relations Contact:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
FAQ
When will Helius Medical Technologies (HSDT) release its Q2 2024 financial results?
What time is the Helius Medical Technologies (HSDT) Q2 2024 earnings call scheduled for?
Who will be hosting the Q2 2024 earnings call for Helius Medical Technologies (HSDT)?
What topics will be discussed in Helius Medical Technologies' (HSDT) Q2 2024 earnings call?
